Stadtmauer, E.A.

(Edward Stadtmauer)

patient bortezomib myeloma therapy response dexamethasone study trial blood neuropathy richardson survival analysis treatment phase transplantation high-dose result mobilization response rate journal ef ﬁcacy cell transplantation cancer collection subgroups lenalidomide cell collection university grade bene ﬁt thalidomide autologou marrow month british journal signi ﬁcantly g-csf impact signi hospital cell mobilization myeloma patients disease metaphase cytogenetics factor number transplant impairment cycle research table department incidence anderson cytogenetic ﬁcacy high-dose dexamethasone apex trial progression high-dose therapy combination dose modi ﬁcation hematology group celgene bortezomib arm randomized blade dexamethasone arm england journal millennium cyclophosphamide haematology dexamethasone patients baseline center british meeting abstracts prognostic

9 Most Recent Publications

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens (Article) Kumar, S. Giralt, S. Miguel, J.S. Ludwig, H. Bergsagel, L. Bladé, J. Lonial, S. Anderson, K.C. Tosi, P. Sonneveld, P. Sezer, O. Vesole, D. Stadtmauer, E.A. Cavo, M. Einsele, H. Richardson, P.G. Durie, B.G.M. Rajkumar, S.V. Harousseau, J-L. Palumbo, A. Bensinger, W. Comenzo, R.L. Lentzsch, S. Munshi, N.C. Niesvizky, R.	2009-11-20
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma (Article) Vogl, D.T. Stadtmauer, E.A. Anderson, K.C. Richardson, P.G. Sonneveld, P. Schuster, M.W. Irwin, D. Facon, T. Harousseau, J-L. Boral, A.L. Neuwirth, R.	2009-11-01
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (Article) Giralt, S. Stadtmauer, E.A. Merlini, G. San Miguel, J. Ludwig, H. Hajek, R. Jagannath, S. Blade, J. Lonial, S. Dimopoulos, M.A. Einsele, H. Barlogie, B. Harousseau, J-L. Anderson, K.C. Gertz, M. Attal, M. Tosi, P. Sonneveld, P. Boccadoro, M. Morgan, G. Sezer, O. Mateos, M.V. Cavo, M. Palumbo, A. Joshua, D. Turesson, I. Chen, W. Shimizu, K. Powles, R. Richardson, P.G. Niesvizky, R. Rajkumar, S.V. Durie, B.G.M. Bensinger, W. Comenzo, R.L. Kumar, S. Munshi, N.C. Dispenzieri, A. Kyle, R.	2009-06-26
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline (Article) Richardson, P.G. Sonneveld, P. Bladé, J. Boccadoro, M. Cavenagh, J. Boral, A.L. Esseltine, D-L. Wen, P.Y. Amato, A.A. Anderson, K.C. San Miguel, J-F. Schuster, M.W. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H. Reece, D.	2009-03-01
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma (Article) Niesvizky, R. Richardson, P.G. Harousseau, J-L. Boral, A.L. Esseltine, D-L. Anderson, K.C. Bladé, J. Rajkumar, S.V. Coleman, M. Rosiñol, L. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T.	2008-10-01
Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study (Article) San Miguel, J-F. Richardson, P.G. Goldschmidt, H. Reece, D. Bladé, J. Boccadoro, M. Cavenagh, J. Neuwirth, R. Boral, A.L. Esseltine, D-L. Anderson, K.C. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S.	2008-04-01
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial (Article) Richardson, P.G. Sonneveld, P. Reece, D. San Miguel, J-F. Bladé, J. Boccadoro, M. Cavenagh, J. Alsina, M. Rajkumar, S.V. Lacy, M. Jakubowiak, A.J. Dalton, W. Schuster, M.W. Boral, A.L. Esseltine, D-L. Schenkein, D. Anderson, K.C. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H.	2007-11-15
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma (Article) Richardson, P.G. Sonneveld, P. Cavenagh, J. Anderson, K.C. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. San Miguel, J-F.	2007-06-01
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (Article) Jagannath, S. Richardson, P.G. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Cowan, J.M. Anderson, K.C.	2007-01-01

Message*:
Your Email Adress*:
	*: Required fields, please provide an email address so that the RePub team can contact you if needed.